BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Pfizer (PFE) rises on arthritis drug study]]>http://www.bloggingstocks.com/2009/06/11/pfizer-pfe-rises-on-arthritis-drug-study/http://www.bloggingstocks.com/2009/06/11/pfizer-pfe-rises-on-arthritis-drug-study/http://www.bloggingstocks.com/2009/06/11/pfizer-pfe-rises-on-arthritis-drug-study/#commentsFiled under: , , , ,

PFE logoPfizer (NYSE: PFE - option chain) shares are rising today after the company gave an update on mid-stage studies of its experimental rheumatoid arthritis drug. A Phase Two study shows PFE's oral JAK-3 inhibitor "demonstrates statistically significant response for patients with rheumatoid arthritis." PFE is currently enrolling patients for a phase 3 study of the treatment. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on PFE.

PFE opened this morning at $14.09. So far today the stock has hit a low of $14.05 and a high of $14.65. As of 11:45, PFE is trading at $14.60 up 55 cents (3.9%). The chart for PFE looks neutral and S&P gives PFE a neutral 3 STARS (out of 5) hold ranking.

Continue reading Pfizer (PFE) rises on arthritis drug study

Pfizer (PFE) rises on arthritis drug study originally appeared on BloggingStocks on Thu, 11 Jun 2009 13:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>arthritisdrug studyDrugStudyinthenewsinvestors observerInvestorsObserveroptionsPFEPfizerThu, 11 Jun 2009 13:10:00 EST<![CDATA[Pfizer is up off the mat -- now is the time to move]]>http://www.bloggingstocks.com/2007/03/22/pfizer-is-up-off-the-mat-now-is-the-time-to-move/http://www.bloggingstocks.com/2007/03/22/pfizer-is-up-off-the-mat-now-is-the-time-to-move/http://www.bloggingstocks.com/2007/03/22/pfizer-is-up-off-the-mat-now-is-the-time-to-move/#commentsFiled under: , , ,

No doubt by now you have heard the good news regarding Pfizer Inc. (NYSE:PFE) and the shield it has in place for Celebrex. You can get some more insight on that by reading Douglas McIntyre's post.

Now the time is ripe for Pfizer to do something powerful. If it can accomplish one or two block buster product releases before mid-year, it'll be off to the races once again. In pursuit of that goal, Pfizer has a large stable of potential ground shakers in development. Here's an encapsulated view of what Pfizer has going right now in R&D:

I counted 49 formulations that Pfizer has in PHASE I of development. Of those compounds, ten are intended cancer treatments, eight are for inflammation and / or pain, including arthritis, 11 are directed towards cardiology, metabolic and endocrine conditions. Pfizer also has six compounds in PHASE I that are indicated for infectious diseases. Phase one drug testing focuses on compound safety rather than drug effectiveness.

Continue reading Pfizer is up off the mat -- now is the time to move

Pfizer is up off the mat -- now is the time to move originally appeared on BloggingStocks on Thu, 22 Mar 2007 10:34:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>approvedarthritiscancercardiocardiovasculardrugepilepsyfibromyalgiaheartHIVIIIIIImalariamedicationobesitypfePfizerphaseregisteredtreatmentThu, 22 Mar 2007 10:34:00 EST